Helsinn’s Family-Business Approach Goes Global In Cancer Care
Executive Summary
Privately-owned Swiss firm preparing for its first solo launch in the US by doubling its sales force.
You may also be interested in...
Deal Watch: Opportunity Knocks For Partnerships In Asia
ApolloBio signs on to take Inovio's HPV immunotherapy into China and Senju and Fosun sign China partnerships – all part of a wave of Chinese companies looking to bring innovative new medicines to the Greater China markets. Meanwhile, GSK signs on with Indian CRO Syngene.
Helsinn Family Business Establishes $50m Start-Up Investment Fund
The family-owned Swiss firm Helsinn has taken its pastoral business approach into the incubation of promising biotech startups by setting up a $50m fund for injecting seed capital into promising prospects.
Deal Worth Up to $464m Advances MEI Drug, Diversifies Helsinn's Portfolio
Helsinn will help MEI Pharma advance its HDAC inhibitor pracinostat into Phase III development via a partnership worth up to $464m.